Navigation Links
Targeted investigational therapy potential to overcome crizotinib resistance in lung cancers
Date:10/20/2013

BOSTON PF-06463922, an investigational drug being developed by Pfizer Inc., has the potential to become a new treatment option for patients who have lung cancer harboring abnormalities in the ALK gene, according to preclinical results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.

About 3 to 5 percent of lung cancers harbor ALK gene abnormalities. The drug crizotinib (Xalkori), which blocks ALK protein kinase activity, was approved in August 2011 by the U.S. Food and Drug Administration for the treatment of patients who have these lung cancers. Although robust responses to crizotinib are observed for lung cancers harboring ALK gene abnormalities, the majority eventually become resistant to the effects of the drug. In many cases, resistance arises because of genetic mutations in ALK.

"Resistance to targeted therapies such as crizotinib is a major challenge when treating patients with cancer," said Tod Smeal, Ph.D., associate research fellow in the Oncology Research Unit at Pfizer Inc. in San Diego, Calif. "Our goal is to take advantage of everything we have learned about designing drugs that target kinases like ALK and the ways in which lung cancers become resistant to crizotinib to develop the best next-generation ALK inhibitor we can.

"Our preclinical studies suggest that we are making progress toward achieving our goal: PF-06463922 has potent ALK-inhibiting activity, it is capable of inhibiting all the crizotinib-resistant ALK mutants so far detected in patients, and it can efficiently access the brain. We are excited about these preclinical results and very hopeful that they will translate into meaningful responses in the clinic."

After carefully designing PF-06463922, Smeal and colleagues first showed in cell assays that it potently inhibited the activity of ALK and all eight of the mutant forms of ALK known to cause resistance to crizotinib
'/>"/>

Contact: Lauren Riley
lauren.riley@aacr.org
215-446-7155
American Association for Cancer Research
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Targeted therapeutics for colon cancer to be presented at AACR meeting
2. First targeted nanomedicine to enter human clinical studies
3. Highly targeted irradiation as good as whole breast radiotherapy in early stage cancer
4. Dana-Farber: Study reports first success of targeted therapy in type of non-small cell lung cancer
5. Inflammatory pathway spurs cancer stem cells to resist HER2-targeted breast cancer treatment
6. Killer infections targeted by hospital study
7. Lower risk of serious side-effects in trials of new targeted drugs
8. Treating drug resistant cancer through targeted inhibition of sphingosine kinase
9. Pitt: Targeted oxidation-blocker prevents secondary damage after traumatic brain injury
10. Deadly witch hunts targeted by grassroots womens groups
11. Large lung cancer study shows potential for more targeted therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2014)... 2014 Written and narrated by award winning ... releases the “The Happiest Man In the World: Life ... of how and why Project C.U.R.E. came to be. , ... Josie and the Reverend Richard W. Jackson, Dr. Jackson exceeded ... 30, but realized that he wasn’t happy. Prompted by this ...
(Date:11/28/2014)... Austin, Texas (PRWEB) November 28, 2014 ... of prediabetes testing and treatment, helped employees learn ... complimentary on-site diabetes blood screening at a local ... Stop Diabetes @ Work initiative. , As ... @ Work program , PreDiabetes Centers is co-hosting ...
(Date:11/28/2014)... Everett, WA (PRWEB) November 28, 2014 ... Snohomish County provides an overview of the influenza virus that ... annual flu season. , The article begins with a ... it manifests its symptoms. It reminds families that children under ... and those suffering from chronic diseases, such as heart and ...
(Date:11/28/2014)... 28, 2014 An inventor from Flint, Mich., ... day. "I got this idea while lying in a hospital ... he said. , The Bed Buddy provides a more ergonomic ... the bathroom. It eliminates the need to leave the bed, ... and dignity. Easy to use and producible in design variations, ...
(Date:11/28/2014)... Most of the people attending a presentation by Ken ... Prince Woods retirement community found out the “prized” possessions ... wouldn’t have made the cut to be on an “Antiques ... decorative and folk art and his appearances on the PBS ... buying and selling antiques. Broadly speaking the antiques market ...
Breaking Medicine News(10 mins):Health News:Thanksgiving Weekend Audiobook Treat! “The Happiest Man In the World: Life Lessons From a Cultural Economist” by Dr. James W. Jackson 2Health News:PreDiabetes Centers Offers Workplace Diabetes Screening at Local School 2Health News:How Flu Vaccines Can Impact Families Is Discussed in New Article from Community Health Center of Snohomish County 2Health News:Antiques Appraiser Sheds Light on "Treasures" 2
... AlertSite(R), a leading,provider of web site performance ... for their customers, announced today that,iHerb.com has chosen ... a major online retailer of brand name nutritional ... ConsumerLab.com as the #1 Online,Supplement Retailer, based on ...
... NEW YORK, Feb. 26 "It is not ... water outweigh risks of,neurodevelopment or other effects such ... Environmental Health report.(1), Fluoride chemicals are added ... reduce tooth decay. Fluoride is found in dental ...
... Feb. 26 With over five million Americans,suffering from ... cases,diagnosed every year, it is the number one cause ... a yearly direct cost of care,estimated at $100 billion, ... Device Markets., Improvements in the care of other ...
... About Medicare, Health Insurance Options, KANSAS CITY, ... boomers turn 62 this year and begin claiming ... the National Association of Insurance,Commissioners (NAIC), many are ... Medicare eligibility., The NAIC,s national survey of ...
... offers a breakthrough in advancing, apoptosis-related research ... medicine, ST. LOUIS, Feb. 26 Sigma-Aldrich(TM) ... that they,have signed a licensing agreement for a ... apoptosis in vitro and in vivo in animals. ...
... Income from Operations, LOVELAND, Colo., Feb. 26 Heska ... fourth quarter, the,three months ended December 31, 2007, and year ... ), Heska Corporation ("Heska" or the "Company") highlights for ... - the highest total revenue in Heska ...
Cached Medicine News:Health News:Top Nutritional Supplement Online Retailer, iHerb.com, Selects AlertSite for Web Site Performance Monitoring 2Health News:Fluoride May Damage the Brain, New Report Says 2Health News:'Hidden Epidemic' of Congestive Heart Failure Driving Hospitalization, Costs 2Health News:Baby Boomers Confused About Medicare, According to Recent NAIC Survey 2Health News:Baby Boomers Confused About Medicare, According to Recent NAIC Survey 3Health News:Baby Boomers Confused About Medicare, According to Recent NAIC Survey 4Health News:Baby Boomers Confused About Medicare, According to Recent NAIC Survey 5Health News:Baby Boomers Confused About Medicare, According to Recent NAIC Survey 6Health News:Sigma-Aldrich Licenses From NeuroSurvival Technologies a Leading Marker for Molecular Imaging of Apoptosis in Vivo 2Health News:Sigma-Aldrich Licenses From NeuroSurvival Technologies a Leading Marker for Molecular Imaging of Apoptosis in Vivo 3Health News:Heska Announces Q4 and Annual 2007 Results 2Health News:Heska Announces Q4 and Annual 2007 Results 3Health News:Heska Announces Q4 and Annual 2007 Results 4Health News:Heska Announces Q4 and Annual 2007 Results 5Health News:Heska Announces Q4 and Annual 2007 Results 6Health News:Heska Announces Q4 and Annual 2007 Results 7Health News:Heska Announces Q4 and Annual 2007 Results 8Health News:Heska Announces Q4 and Annual 2007 Results 9Health News:Heska Announces Q4 and Annual 2007 Results 10
(Date:11/26/2014)... , November 26, 2014 A ... of the organ protrudes through the wall of a weak ... area at birth are some of the causes of hernias. ... hiatal, femoral, and incisional. An inguinal hernia is when part ... umbilical hernia is found in the area of the umbilicus. ...
(Date:11/26/2014)... , Nov. 26, 2014  Aridis Pharmaceuticals, ... produce novel therapies for infectious diseases, announced today ... an internationally recognized key opinion leader in the ... scientific advisory board. Founder and Chief ... "We believe Dr. Opal,s extensive experience investigating bacterial ...
(Date:11/26/2014)... 25, 2014 According to ... Power Source (Electric, Battery, Pneumatic), by Product (Drill, ... Cart), by Application (Orthopedic, ENT, Oral, Thoracic, Neurology) ... global Powered Surgical Instruments Market is estimated to ... 2014 and is expected to grow at a ...
Breaking Medicine Technology:Global Hernia Repair Devices Market Size, Share, Trends and Forecast 2014 to 2018 - Big Market Research 2Global Hernia Repair Devices Market Size, Share, Trends and Forecast 2014 to 2018 - Big Market Research 3Global Hernia Repair Devices Market Size, Share, Trends and Forecast 2014 to 2018 - Big Market Research 4Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 2Aridis Pharmaceuticals Appoints Dr. Steven Opal to Scientific Advisory Board 3Powered Surgical Instruments Market Worth $2.1 Billion by 2019 2Powered Surgical Instruments Market Worth $2.1 Billion by 2019 3Powered Surgical Instruments Market Worth $2.1 Billion by 2019 4
... Arena Pharmaceuticals, Inc. (NASDAQ: ARNA ) announced ... the Citi 2012 Global Health Care Conference on Wednesday, February ... Time) at the Waldorf=Astoria in New York City. Jack Lief, ... a corporate overview. A live audio webcast of ...
... Switzerland, Feb. 23, 2012  Auxilium Pharmaceuticals, Inc. ... Pharmaceuticals Ltd. (SWX: ATLN.S) announced today that ... for the development, supply and commercialization of ... biologic for the potential treatment of Dupuytren,s ...
Cached Medicine Technology:Arena Pharmaceuticals to Present at the Citi 2012 Global Health Care Conference 2Arena Pharmaceuticals to Present at the Citi 2012 Global Health Care Conference 3Auxilium Pharmaceuticals, Inc. and Actelion Pharmaceuticals Ltd. Enter a Collaboration Agreement for XIAFLEX® in Canada, Australia, Brazil and Mexico 2Auxilium Pharmaceuticals, Inc. and Actelion Pharmaceuticals Ltd. Enter a Collaboration Agreement for XIAFLEX® in Canada, Australia, Brazil and Mexico 3Auxilium Pharmaceuticals, Inc. and Actelion Pharmaceuticals Ltd. Enter a Collaboration Agreement for XIAFLEX® in Canada, Australia, Brazil and Mexico 4Auxilium Pharmaceuticals, Inc. and Actelion Pharmaceuticals Ltd. Enter a Collaboration Agreement for XIAFLEX® in Canada, Australia, Brazil and Mexico 5Auxilium Pharmaceuticals, Inc. and Actelion Pharmaceuticals Ltd. Enter a Collaboration Agreement for XIAFLEX® in Canada, Australia, Brazil and Mexico 6
These are the Reusable Components (minus cannula), to be used with the VersaStep™ Plus Reposable Short System....
The VersaStep™ 5 mm and VersaStep™ PLUS Reposable system components for creating each access port are supplied in separate packages....
VersaStep™ Reposable Sterilization Trays....
... Instrument for applications in ... ,The VERSASTEP™ Plus instrument ... length is a unique ... radial dilation. It is ...
Medicine Products: